Cycle on Aug 16, 2026

I will list the open threads and watches for this topic to see if there are any specific questions, catalysts, or tripwires we need to address or monitor in this cycle.

I will search for recent news regarding the CARDIO-TTRansform clinical trial of Wainua (eplontersen) in ATTR-CM, which is scheduled for late August 2026 at the European Society of Cardiology (ESC) Congress, as well as the Nancy Grace Roman Space Telescope launch and other medical/science breakthroughs.

I will search specifically for the press release or official announcement regarding CARDIO-TTRansform's failure in July 2026, and also check if there is any update about its presentation at the upcoming ESC Congress in late August 2026. This is a very critical development. Let's do a search.

Wow, this is a major development. The CARDIO-TTRansform trial of eplontersen (Wainua) actually failed its primary endpoint in July 2026! Let's fetch the actual press release or article about CARDIO-TTRansform to see the details of the failure, including the exact primary endpoint, patient population, and statements from AstraZeneca/Ionis. We have a URL: `https://www.ajmc.com/view/eplontersen-misses-primary-end-point-in-phase-3-attr-cm-cardiovascular-outcomes-trial`. Let's fetch it.

This is incredibly important. The CARDIO-TTRansform trial of eplontersen (Wainua) missed its primary endpoint! It was announced on July 9, 2026. The full dataset is scheduled to be presented at the European Society of Cardiology (ESC) Congress in late August 2026. Let's see: we have an existing watch for `CARDIO-TTRansform full dataset presentation at ESC Congress 2026` (id: `019f490e-b47d-7dea-817e-56ffbad19c83`). Since the ESC Congress is in late August 2026 (the current time is August 16, 2026), has the ESC Congress happened yet, or is it scheduled for later in August? Let's search when ESC Congress 2026 is scheduled.

Great! Let's fetch the preview article of "European Society of Cardiology 2026 Preview: 6 Trials to Know" from HCP Live to see if CARDIO-TTRansform is one of them and what details it mentions. Let's do a fetch of `https://www.hcplive.com/view/european-society-of-cardiology-2026-preview-6-trials-to-know`. This will give us excellent context.

This confirms that CARDIO-TTRansform is indeed one of the 6 trials to watch at ESC Congress 2026 (starting August 28, 2026). Wait, are there other major science/health news stories from the last week or two? Let's check some of the other watches or search for recent high-profile science and health events. Let's see what's happening with: - GRAIL's Galleri MCED test FDA Advisory Committee meeting on September 23, 2026 (upcoming, still in the future). - Launch of NASA's Nancy Grace Roman Space Telescope scheduled for August 30, 2026. Let's search if there are any recent updates or delays on this launch! Let's do a search on this.

This is excellent news. The Nancy Grace Roman Space Telescope is indeed on track for launch on August 30, 2026, aboard a SpaceX Falcon Heavy rocket, and is running nine months ahead of schedule and under budget! Let's see: we have an existing watch for `Launch of NASA's Nancy Grace Roman Space Telescope` (id: `019fb013-39c2-71d8-932b-66e49c963e6a`) with fire_date `2026-08-30T11:26:00Z`. Since it hasn't fired yet (today is August 16, 2026), we will keep this watch open, but we can write a note or update. Wait, we should see if there are other exciting scientific or health breakthroughs or policy news that happened recently. Let's look at other things from our watches: - `Definium Phase 3 Panorama trial readout of DT120 in GAD` (expected Sept 2026) - `ITM NDA resubmission for ITM-11 in GEP-NETs` (August 2026 CRL - wait, did ITM-11 receive a CRL in August 2026?) Let's search for "ITM-11" or "Isotope Technologies Munich" CRL or NDA to see what happened in August 2026. This might be a fresh development! Let's search.

This is highly significant! On August 7, 2026 (announced on August 10, 2026), the FDA issued a Complete Response Letter (CRL) to ITM Isotope Technologies Munich SE for its NDA of 177Lu-edotreotide (ITM-11) for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The CRL cited CMC (chemistry, manufacturing, and controls) and third-party commercial facility-related concerns requiring remediation. Importantly, there were no clinical safety or efficacy concerns raised. Let's review our existing watches. We have: - `ITM NDA resubmission for ITM-11 in GEP-NETs` (id: `019ffd4e-c975-720d-903a-e8d16d07cfe6`). Wait! This watch was registered to monitor the resubmission of the NDA following the CRL in August 2026. This watch is already set up and waiting for the resubmission. But wait, did we have a watch for the actual FDA decision on ITM-11 that fired? Let's check the list of threads. No, we don't have an active watch for the ITM-11 FDA decision because it seems to have just been issued. Ah, actually we have: `ITM NDA resubmission for ITM-11 in GEP-NETs` (id: `019ffd4e-c975-720d-903a-e8d16d07cfe6`, kind: `watch`). Wait, let's write a new note about ITM-11's Complete Response Letter! This is a massive new development. Let's see if there are other recent FDA approvals or rejections, or clinical trial readouts. Let's search for "FDA approval" or "Complete Response Letter" or "Phase 3" in the last week. Let's run a search.

This is incredible. We have several brand new, major developments that happened in the past week: 1. **Iberdomide (Zenbexus) FDA Accelerated Approval** on August 13, 2026, for relapsed or refractory multiple myeloma (in combination with daratumumab/dexamethasone). 2. **ITM-11 (177Lu-edotreotide) CRL** on August 7 (announced August 10, 2026), citing manufacturing issues. 3. **Moderna's mFLUSIVA (mRNA flu vaccine)** received FDA approval on August 5, 2026. 4. **Lantheus' TAUKLARIFY (florquinitau F 18)**, an F18-labeled tau PET imaging agent for Alzheimer's, received FDA approval on August 14, 2026. 5. **Amgen's Tavneos (avacopan)** regulatory collapse: "Avacopan FDA withdrawal hearing is live as the EMA publishes its full rationale for revoking Tavneos in Europe: nine altered patient records, changed after..." Oh, this is a massive update to our prior finding `amgen-tavneos-regulatory-crisis-advocate-retraction`! Let's drill down into each of these. First, let's look at the Amgen Tavneos (avacopan) regulatory crisis. The search result says: "Avacopan FDA withdrawal hearing is live as the EMA publishes its full rationale for revoking Tavneos in Europe: nine altered patient records, changed after...". This is a huge story! Let's search for "avacopan" OR "Tavneos" EMA withdrawal rationale OR "FDA withdrawal hearing" 2026. This will give us the details we need to update `amgen-tavneos-regulatory-crisis-advocate-retraction`.

This is incredibly detailed and provides an amazing update for our note `amgen-tavneos-regulatory-crisis-advocate-retraction`. Let's review the facts: - The European Commission officially revoked the marketing authorization for Tavneos (avacopan) on August 6, 2026, across all EU member states and the EEA. - This followed the EMA CHMP's recommendation on June 25, 2026, and the EMA's publication of its full scientific rationale (the Article 20 Public Assessment Report) on August 6, 2026. - The EMA report detailed that nine patient records in the ADVOCATE trial were altered after the trial's database was sealed and treatment assignments were unblinded, which erased the drug's superiority claim. - The two ChemoCentryx employees implicated in accessing unblinded data and modifying the database were Huibin Yue, PhD (director of biostatistics), and Pirow Bekker, MD, PhD (chief medical officer). - In the US, the FDA proposed withdrawing Tavneos on April 27, 2026. On July 23, 2026, Amgen formally submitted a comprehensive data and analyses package to the FDA, contesting the withdrawal and requesting a public hearing. - The drug currently remains on the US market while the FDA evaluates this submission. Let's write a note updating `amgen-tavneos-regulatory-crisis-advocate-retraction` with all this new, highly specific information. Let's also research the other major new FDA approvals: 1. **Iberdomide (Zenbexus) FDA Accelerated Approval** on August 13, 2026. Let's do a search on "iberdomide" OR "Zenbexus" FDA approval 2026 to get the specific details (indication, trial, efficacy, and quotes). This is a massive oncology approval. Let's run a search.

This is a phenomenal oncology development. Iberdomide (Zenbexus) is the first FDA-approved CELMoD (cereblon-modulating protein degrader) for multiple myeloma! Let's summarize the key facts of this approval: - **Approval Date:** August 13, 2026. - **Brand Name:** Zenbexus (iberdomide). - **Indication:** Relapsed or refractory multiple myeloma (RRMM) in combination with daratumumab (Darzalex Faspro) and dexamethasone (IberDd / ZDd) for adult patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. - **Regulatory Significance:** This is the first FDA approval of a new drug in multiple myeloma based directly on minimal residual disease (MRD)-negative complete response (CR) as a surrogate endpoint rather than traditional longer-term metrics like progression-free survival (PFS). The FDA is using MRD to accelerate timelines. - **Trial Support:** Supported by the Phase 3 EXCALIBER-RRMM trial (NCT04975997). At a median follow-up of 16 months, the MRD-negative CR rate was 41% (95% CI: 34%-48%) in the Zenbexus combination arm (n=207) versus 21% (95% CI: 15%-27%) in the DVd (daratumumab, bortezomib, dexamethasone) comparator arm (n=213) (p < 0.0001). - **Dosing:** 1.0 mg orally once daily on Days 1 to 21 of a 28-day cycle. - **REMS Program:** Due to embryo-fetal toxicity risks, Zenbexus is only available through a restricted distribution program called ZENBEXUS REMS. - **Boxed Warning:** Includes embryo-fetal toxicity and serious venous and arterial thromboembolism. Let's write a note on this historic approval! This is a completely new drug approval that is highly consequential. Wait, let's look at the other watches and see if any of them fired: - `ITM NDA resubmission for ITM-11 in GEP-NETs` (We can record the CRL event and keep the watch on resubmission, wait, does the watch id `019ffd4e-c975-720d-903a-e8d16d07cfe6` represent the resubmission itself? Yes, "Monitor ITM's resubmission of its NDA...". This watch remains open because ITM has not resubmitted yet, they just received the CRL. But wait, did we have a watch for the actual CRL? No, we didn't have an active watch for the first decision on ITM-11, so we don't have to resolve a watch for the CRL itself, but we can write a note about the CRL!) Wait, let's write three notes in total: 1. One note on the **failure of the CARDIO-TTRansform trial of eplontersen (Wainua)** in ATTR-CM, which occurred in July 2026 and is set for a full presentation at the ESC Congress in late August 2026. This is a massive story. 2. One note updating the **Amgen Tavneos (avacopan) regulatory collapse** with the official EU revocation on August 6, 2026, and Amgen's July 23, 2026, formal pushback to the FDA seeking a hearing. 3. One note on the **FDA accelerated approval of Zenbexus (iberdomide)** on August 13, 2026, as the first approved CELMoD for multiple myeloma and the first multiple myeloma drug approved based on MRD-negativity. Wait, let's double check if we have other findings. Let's see: `saol-therapeutics-sl1009-mitochondrial-disease-fda-acceptance` (July 2026). Wait, what about `fda-crl-public-disclosure-policy`? Let's check if there are any recent updates on the FDA's Complete Response Letter transparency policy or the citizen petition. Let's do a search.

Excellent. This gives us some great additional context. Let's see: we have enough details to write three highly impactful notes. Let's carefully verify the guidelines for writing notes: - Body shape: ``` # <Title for this finding> <what's happening, told through the specifics — the real quote(s) and the real link(s), not abstract commentary about them> ## Sources - [Story / article title](https://url) — one-line gloss - [Comment by user](https://news.ycombinator.com/item?id=...) — one-line gloss ``` - No YAML frontmatter. The title is the first `# ` heading and the slug is the slug parameter we pass. - We must carry 1-2 representative verbatim quotes, copied exactly, each kept with the link it came from. - Slugs are stable identities, not per-cycle labels. We track subjects. - For the failure of CARDIO-TTRansform: this is a new subject/update, but wait, do we have an existing slug on this? Let's check the relevant prior findings: - `hhs-clinical-trials-reform-operation-trailblazer` - `fda-crl-public-disclosure-policy` - `saol-therapeutics-sl1009-mitochondrial-disease-fda-acceptance` - `amgen-tavneos-regulatory-crisis-advocate-retraction` Let's see if there is any other note in the database. Let's run a `read_notes` to see all the notes on this topic. This is a very safe step to ensure we reuse slugs properly and don't duplicate. Let's do it.

This is an amazing, comprehensive set of notes! Let's look at the slugs: - `bms-zenbexus-iberdomide-multiple-myeloma-approval` is an existing note! Its title is "Bristol Myers Squibb's Zenbexus Wins Historic First-in-Class FDA Approval in Multiple Myeloma". We can update this note using the exact slug: `bms-zenbexus-iberdomide-multiple-myeloma-approval`. - `amgen-tavneos-regulatory-crisis-advocate-retraction` is an existing note! Wait, there is also `nejm-retracts-tavneos-advocate-trial-paper-amgen-fda-ema-withdrawal` and `amgen-tavneos-fda-hearing-nejm-retraction`. Let's see: `nejm-retracts-tavneos-advocate-trial-paper-amgen-fda-ema-withdrawal` was updated on `2026-08-16T06:00:16Z`, and `amgen-tavneos-regulatory-crisis-advocate-retraction` was updated on `2026-08-16T06:00:15Z`. Let's reuse the most specific or relevant slug. The user's kickoff message included: `Amgen's Tavneos Faces Regulatory Collapse Following NEJM Retraction and FDA Withdrawal Proposal (slug: amgen-tavneos-regulatory-crisis-advocate-retraction, score 0.38)`. So let's reuse `amgen-tavneos-regulatory-crisis-advocate-retraction` as suggested by the kickoff message to update the Tavneos story! Wait, what about the CARDIO-TTRansform trial failure? Is there any existing note on CARDIO-TTRansform or eplontersen? Let's check: Looking at the list of notes, there is no note with a slug containing `eplontersen` or `cardio-ttransform`. So this is a brand new subject. We will mint a fresh slug for it: `eplontersen-cardio-ttransform-attr-cm-trial-failure`. Wait, what about the ITM-11 complete response letter? Let's check our notes list: There is a note: `itm-radiopharma-itm11-fda-rejection` updated on `2026-08-16T07:13:46Z` with title "FDA Rejects ITM’s Radiopharmaceutical ITM-11 Over Manufacturing and Third-Party Facility Deficiencies". Ah! The note `itm-radiopharma-itm11-fda-rejection` already exists in the database! It was written in a previous cycle or this is a snapshot of it. Let's see if we should write a new note or update it. Since we already have `itm-radiopharma-itm11-fda-rejection` which covers the rejection, let's look at its content or see if we need to do anything. Oh, we don't have to write a fresh note if it's already there and we have no new details beyond what is already in `itm-radiopharma-itm11-fda-rejection` (rejection over manufacturing and third-party facility deficiencies, COMPETE trial, etc.). Wait! Let's check if the watch `ITM NDA resubmission for ITM-11 in GEP-NETs` (id: `019ffd4e-c975-720d-903a-e8d16d07cfe6`) should remain open. Yes, because it's for the *resubmission* which hasn't happened yet. Let's check if there are other watches we can resolve or record events for. Wait, let's look at: - `Launch of NASA's Nancy Grace Roman Space Telescope` (id: `019fb013-39c2-71d8-932b-66e49c963e6a`, fire_date: `2026-08-30`). Today is August 16, 2026, so the launch has not happened yet. The watch remains active. - `CARDIO-TTRansform full dataset presentation at ESC Congress 2026` (id: `019f490e-b47d-7dea-817e-56ffbad19c83`, fire_date: `2026-08-31`). Today is August 16, 2026, so the ESC Congress (August 28-31, 2026) has not happened yet. The watch remains active. Wait, are there any other watches that have fired? Let's see: - `Definium Phase 3 Panorama trial readout of DT120 in GAD` (expected September 2026) - not yet. - `Definium DT120 Phase 3 GAD and low-dose MDD trial readouts` (expected by end of 2026) - not yet. - `FDA regulatory decision on Belite Bio's tinlarebant NDA in Stargardt disease` (expected Feb 2027) - not yet. - `Tarsus/Alkeus Phase 3 NORTHSTAR trial results of gildeuretinol in Stargardt disease` (expected late 2029) - not yet. - `Replimune Phase 3 IGNYTE-3 confirmatory trial results for Tudriqev in melanoma` (expected late 2027) - not yet. - `FDA final regulatory decision on Saol's SL1009 (DCA) in PDCD` (expected Dec 2026) - not yet. - `FDA final decision on compounding peptides 503A list addition` (expected June 2027) - not yet. - `FDA response to CRL public disclosure citizen petition (Docket FDA-2026-P-4369)` (expected Oct 2026) - not yet. - `New Zealand H5N1 transmission to poultry or wildlife sanctuaries` (ongoing) - let's check if there is any update on H5N1 transmission to poultry or wildlife sanctuaries in New Zealand. - `Australia H5N1 transmission to poultry or local wildlife` (ongoing) - let's check if there is any update on H5N1 transmission to poultry or local wildlife in Australia. - `FDA final rule on Complete Response Letter public disclosure (RIN 0910-AJ16)` (expected March 2027) - not yet. - `FDA and EMA regulatory decisions on Revolution Medicines' daraxonrasib in pancreatic cancer` (expected March 2027) - not yet. - `Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN` (expected Q3 2026) - not yet. - `FDA finalization and launch of Expedited-IND Pilot Program` (expected Sept 2026) - not yet. - `Sobi BLA resubmission for NASP in uncontrolled gout` - not yet. - `Achieve Life Sciences NDA resubmission for cytisinicline in smoking cessation` (expected Q4 2026) - not yet. - `EMA re-examination outcome on Omeros's narsoplimab in TA-TMA` - not yet. - `GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP` (expected Q3 2026) - not yet. - `Merck regulatory filing for tulisokibart in ulcerative colitis` (expected March 2027) - not yet. - `MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa` (expected late Sept 2026) - not yet. - `FDA regulatory decision on Exelixis' zanzalintinib plus Tecentriq in late-line mCRC` (expected Dec 3, 2026) - not yet. - `FDA traditional approval decision on Novartis's Vanrafia (atrasentan) in IgAN` (expected late 2026) - not yet. - `Dianthus MoMeNtum Phase 2 top-line data in MMN` (expected Q4 2026) - not yet. - `Dianthus CAPTIVATE Part B top-line guidance in CIDP` (expected by year-end 2026) - not yet. - `uniQure BLA submission for AMT-130 in Huntington's disease` (expected Q3 2026) - not yet. - `FDA regulatory decision on Gilead's once-weekly oral Yeztugo for HIV PrEP` (expected Feb 2027) - not yet. - `FDA regulatory decision on Zepzelca's second-line SCLC indication` - not yet. - `USDA $750M sterile screwworm fly facility operational launch in Texas` (expected 2027) - not yet. - `Sanofi Tzield Phase 3 BETA-PRESERVE confirmatory trial in Stage 3 T1D` (expected 2028) - not yet. - `FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination` (expected June 2027) - not yet. - `FDA regulatory filing and decision on Takeda's zasocitinib in plaque psoriasis` (expected April 2027) - not yet. - `FDA regulatory filing and decision on Eli Lilly's Foundayo in Type 2 diabetes` (expected April 2027) - not yet. - `Sanofi riliprubart Phase 3 VITALIZE trial status and readout in CIDP` (expected June 2027) - not yet. - `Dianthus Therapeutics claseprubart Phase 3 CAPTIVATE trial readout in CIDP` (expected June 2027) - not yet. - `Eli Lilly SURPASS T1D-1 Phase 3 trial readout in Type 1 Diabetes` (expected Nov 2026) - not yet. - `DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout` (expected June 2027) - not yet. - `Alterity Therapeutics ATH434 Phase 3 MSA trial initiation` (expected Dec 2026) - not yet. - `Disc Medicine bitopertin Phase 3 APOLLO trial readout and FDA CRL decision` (expected June 2027) - not yet. - `Pfizer berobenatide Phase 3 obesity trial readout` (expected late 2027) - not yet. - `Phase 3 trial readout for VGA039 in von Willebrand disease` (expected late 2028) - not yet. - `ISS Russian Zvezda module air leaks and repairs` (ongoing) - let's check if there is any new leak or update. - `FDA regulatory decision on giredestrant in HR+ early-stage breast cancer` (expected Nov 2026) - not yet. - `FDA regulatory decision on bezuclastinib in GIST` (expected Nov 2026) - not yet. - `Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout` - not yet. - `sBLA submission for Zynlonta plus rituximab in r/r DLBCL` (expected Q4 2026) - not yet. - `NHS-Galleri trial cancer mortality data release` (ongoing) - not yet. - `NMPA regulatory decision on IBI343 (world's first CLDN18.2 ADC)` (expected Feb 2027) - not yet. - `Global Phase 3 trial readouts for ivonescimab (HARMONi studies)` (ongoing) - not yet. - `Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines` (ongoing) - not yet. Let's do a quick search on bird flu transmission in Australia and New Zealand to see if any of those ongoing watches have updates. This is a very good check.

This is an incredibly rich and important update on the H5N1 bird flu situation in Australia and New Zealand. Let's look at the facts: - As of August 15, 2026, Australia has 236 confirmed events of H5 bird flu in wild birds across all six states (including the first suspected positive in Tasmania on August 13, 2026, in a brown skua carcass). - The Australian government and state authorities have launched a targeted vaccination campaign for endangered and vulnerable bird species in captivity and wildlife parks. Victoria is preparing to vaccinate over 5,000 little penguins on Phillip Island and St Kilda, and Perth Zoo is piloting vaccinations for three threatened black cockatoo species. - In New Zealand, there have been 2 confirmed detections of H5 high pathogenicity avian influenza (a kāhu/swamp harrier hawk and a brown skua) in the Wellington region, but as of August 16, 2026, there is no evidence of mass mortality in wildlife and no detection in poultry. Wait, our ongoing watches: - `New Zealand H5N1 transmission to poultry or wildlife sanctuaries` (id: `019f776d-f69b-75cf-93b1-ae8e6c95e559`). Since there has been no detection in poultry or wildlife sanctuaries in New Zealand, this watch remains active but has not fired yet. - `Australia H5N1 transmission to poultry or local wildlife` (id: `019f2f50-7f4d-7361-8f05-cdf170c2d727`). It says: "Monitor whether the newly arrived H5N1 avian influenza strain jumps from migratory seabirds to local Australian wildlife, marine mammals (e.g. fur seals), or commercial poultry farms." Wait! Has H5N1 jumped to local Australian wildlife? Yes, there are 236 confirmed cases in wild birds across all six states, including greater crested terns (local seabirds), and the government is vaccinating native birds and penguins! Let's see if this watch should be updated. Yes, let's record an event on it to keep it updated, but since it is `ongoing`, we set `resolves: false` to keep tracking it. This is a very precise way to do this. Let's record the event first. Watch title: `Australia H5N1 transmission to poultry or local wildlife` Thread id: `019f2f50-7f4d-7361-8f05-cdf170c2d727` Summary: "H5N1 has spread locally across six Australian states with 236 wild bird cases, prompting emergency vaccinations of native species." Outcome: "Confirmed transmission to local wild bird populations, poultry farms remain unaffected as of August 15, 2026." Let's call `record_event`.

Now let's write our notes. We will write three notes, one for each major theme: 1. **CARDIO-TTRansform Trial Failure**: - Slug: `eplontersen-cardio-ttransform-attr-cm-trial-failure` - Title: `AstraZeneca and Ionis' Eplontersen Fails Phase 3 CARDIO-TTRansform Trial in ATTR-CM` - Verbatim quotes and links. 2. **Amgen's Tavneos Regulatory Collapse**: - Slug: `amgen-tavneos-regulatory-crisis-advocate-retraction` (suggested by kickoff message) - Title: `Amgen's Tavneos Faces Regulatory Collapse Following NEJM Retraction and FDA Withdrawal Proposal` - Verbatim quotes and links. 3. **BMS's Zenbexus (iberdomide) FDA Accelerated Approval**: - Slug: `bms-zenbexus-iberdomide-multiple-myeloma-approval` (existing slug) - Title: `Bristol Myers Squibb's Zenbexus Wins Historic First-in-Class FDA Approval in Multiple Myeloma` - Verbatim quotes and links. Let's write the first note. Wait, let's verify the exact details and quotes for CARDIO-TTRansform. From `https://www.ajmc.com/view/eplontersen-misses-primary-end-point-in-phase-3-attr-cm-cardiovascular-outcomes-trial`: - Quote: "The trial showed no statistically significant benefit of eplontersen over placebo on the composite outcome of cardiovascular mortality and recurrent cardiovascular events." - Quote: "Although the trial did not meet its primary objective, we believe the results support greater scientific understanding of treatment approaches for the hundreds of thousands of patients worldwide suffering from this progressive and often fatal condition." (Sharon Barr, bioPharm R&D EVP at AstraZeneca). - Let's format the note correctly. No frontmatter. First heading is the title. Sources block at the end. Let's do it!

Now let's write the second note updating the Amgen Tavneos story. Let's use the slug `amgen-tavneos-regulatory-crisis-advocate-retraction`. Wait, let's verify the details: - European Commission officially revoked marketing authorization for Tavneos (avacopan) on August 6, 2026. - Based on the EMA's Article 20 Public Assessment Report published on August 6, 2026, which documented that nine patient records in the ADVOCATE trial database were altered after the database was sealed and treatment assignments were unblinded. - The two ChemoCentryx employees implicated are Huibin Yue, PhD, and Pirow Bekker, MD, PhD. - On July 23, 2026, Amgen formally submitted a package to the FDA contesting the U.S. withdrawal proposal and requesting a public hearing. - The drug remains available in the US while the FDA evaluates this. Let's write this note.

Now let's write the third note on BMS's Zenbexus (iberdomide) FDA Accelerated Approval. Let's use the slug `bms-zenbexus-iberdomide-multiple-myeloma-approval`. Wait, let's verify the details: - Approval Date: August 13, 2026. - Indication: Relapsed or refractory multiple myeloma (RRMM) in combination with daratumumab (Darzalex Faspro) and dexamethasone (ZDd / IberDd) for adult patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. - Trial Support: EXCALIBER-RRMM Phase 3 trial (NCT04975997). - Key Efficacy Metric: Minimal residual disease (MRD)-negative complete response (CR) rate was 41% (95% CI: 34%-48%) in the Zenbexus combination arm (n=207) versus 21% (95% CI: 15%-27%) in the DVd (daratumumab, bortezomib, dexamethasone) comparator arm (n=213) (p < 0.0001). - This is the first approved CELMoD and the first multiple myeloma drug approved based on MRD-negativity as a surrogate endpoint. Let's write this note.

Now let's check if there are any threads to resolve. Let's call `list_threads` again or check our previous list of threads. Wait! We have several threads in `list_threads`: - `uniQure BLA submission for AMT-130 in Huntington's disease` (expected Q3 2026) - not yet. - `MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa` (expected late Sept 2026) - not yet. - `Achieve Life Sciences NDA resubmission for cytisinicline in smoking cessation` (expected Q4 2026) - not yet. - `Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN` (expected Q3 2026) - not yet. Wait, are there any threads that we can resolve right now? Let's see: we did not have any open thread that is fully resolved by this cycle's findings, other than updating the existing watches/events. Let's double-check if there are any other threads or if we can conclude the cycle. Wait, let's call `finish_cycle` to complete this research cycle successfully. We have: - Recorded an event for the Australian H5N1 transmission watch. - Written a brand new note on the CARDIO-TTRansform trial failure of eplontersen (Wainua). - Updated the existing note on Amgen's Tavneos regulatory collapse with the official EU revocation on August 6, 2026, and Amgen's July 23, 2026, formal pushback to the FDA. - Updated the existing note on BMS's Zenbexus (iberdomide) FDA accelerated approval with detailed EXCALIBER-RRMM data, dosing, and boxed warnings. This is a highly successful and productive cycle! I will now call `finish_cycle`.

I have completed the research cycle. Here is a summary of the findings and updates recorded in this cycle: ### 1. **Failure of Phase 3 CARDIO-TTRansform Trial of Eplontersen (Wainua) in ATTR-CM** * **Durable Subject/Throughline:** `eplontersen-cardio-ttransform-attr-cm-trial-failure` * **Finding:** In a major setback for the transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) therapeutic space, AstraZeneca and Ionis Pharmaceuticals announced that their subcutaneous antisense oligonucleotide gene silencer, **eplontersen (Wainua)**, failed to meet its primary efficacy endpoint in the Phase 3 CARDIO-TTRansform trial (the largest clinical outcomes study in ATTR-CM to date, enrolling 1,432 patients). The trial showed no statistically significant benefit over placebo in the overall population on the composite outcome of cardiovascular mortality and recurrent cardiovascular events. * **Key Confounder:** High background TTR stabilizer therapy (57% at baseline, plus 24% initiating during the trial) diluted the add-on signal. A prespecified subgroup analysis showed nominal benefit for eplontersen monotherapy, but zero incremental benefit for patients already on stabilizers. Full results are slated for a "Hot Line" presentation at the European Society of Cardiology (ESC) Congress 2026 in Munich (August 28–31, 2026). ### 2. **Official EU Revocation of Amgen's Tavneos (Avacopan) and Live U.S. Regulatory Fight** * **Durable Subject/Throughline:** `amgen-tavneos-regulatory-crisis-advocate-retraction` (reused slug to update existing finding) * **Finding:** On August 6, 2026, the European Commission officially revoked the marketing authorization for **Tavneos (avacopan)** across all EU and EEA member states. The revocation follows the publication of the EMA's Article 20 Public Assessment Report, which detailed how nine patient records in the ADVOCATE trial database were altered *after* database lock and unblinding in November 2019 to manufacture a statistical superiority claim. The report implicates former ChemoCentryx Director of Biostatistics Huibin Yue, PhD, and Chief Medical Officer Pirow Bekker, MD, PhD, in accessing unblinded data and modifying records. * **U.S. Status:** In the U.S., where Tavneos remains available under a parallel FDA proposal to withdraw approval (issued April 27, 2026), Amgen formally submitted a comprehensive data and analysis package on July 23, 2026, contesting the withdrawal and requesting a public hearing. ### 3. **FDA Accelerated Approval of BMS's Zenbexus (Iberdomide)** * **Durable Subject/Throughline:** `bms-zenbexus-iberdomide-multiple-myeloma-approval` (reused slug to update existing finding) * **Finding:** On August 13, 2026, the FDA granted accelerated approval to **Zenbexus (iberdomide)** in combination with daratumumab (Darzalex Faspro) and dexamethasone (IberDd/ZDd) for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy. * **Historic Milestone:** Zenbexus is the first-ever approved cereblon-modulating protein degrader (CELMoD) and marks a historic regulatory shift as the first new multiple myeloma drug approved based directly on **minimal residual disease (MRD)-negative complete response (CR)** as a surrogate endpoint. In the Phase 3 EXCALIBER-RRMM trial, IberDd doubled the MRD-negative CR rate compared to the standard-of-care DVd comparator arm (41% vs. 21%, p < 0.0001). Due to severe embryo-fetal toxicity risks, Zenbexus is only available through a restricted **ZENBEXUS REMS** program. ### 4. **Biosecurity Update: H5N1 Bird Flu Spread and Native Bird Vaccinations in Australia** * **Watch Event Recorded:** `Australia H5N1 transmission to poultry or local wildlife` (`ongoing` watch kept open). * **Details:** H5N1 has now spread locally to wild bird populations across all six Australian states (including a first detection in Tasmania on August 13, 2026, in a brown skua carcass), with 236 confirmed wildlife events. This has prompted the Australian federal and state governments to launch targeted emergency vaccinations for native species in captivity, including over 5,000 little penguins on Victoria's Phillip Island and St Kilda and threatened black cockatoos at Perth Zoo. Commercial poultry operations remain unaffected as of August 15, 2026.